Efectividad Y Costo-Efectividad De La Fluoración Del Agua En La Prevención De Caries Dental

Abstract

budget impact analysys a target population of 550 patients is estimated and three scenarios of ustekinumab adoption were assessed: current scenario (13% market share), middle penetration scenario (28% market share) and a high penetration scenario (50% of market share). No discount rate was used. Exchange rate (1 USD = 1,794 COP). Results: Total cost per patient (USD): ustekinumab (23,229), etanercept (25,079) and adalimumab (23,825). PASI 50 response (% of patients): ustekinumab (90%), etanercept (76%) and adalimumab (81%). Cost per responder patient: ustekinumab (25,810), etanercept (32,999) and adalimumab (29414). Budget Impact (USD): current scenario (13,387,999), middle penetration scenario (13,262,955) and high penetration scenario (13,114,969). ConClusions: When a subcutaneous biologic is considered as the first line choice of treatment for psoriasis, ustekinumab is the prefered first line therapy. Ustekinumab progressive adoption, in the Colombian Health System, demonstrates potential savings driven by its better efficacy and less probability of requiring a second line more expensive treatment.